With successful tyrosine kinase inhibitor treatment, the vast majority of chronic myeloid leukaemia patients diagnosed in chronic phase achieve long-term leukaemia-free survival as well as deep molecular responses. Accurate assessment of residual disease by RT-qPCR not only allows patients at risk of treatment failure to be segregated for treatment intensification but also identify patients with deep molecular responses for treatment cessation studies in the future. Specificity, sensitivity and accuracy of the RT-qPCR assay depend on optimised methodology and high-quality specimens with minimal RNA degradation. International standardisation projects allow for RT-qPCR results to be compared across laboratories and in clinical studies. For patients who fail to achieve a desired treatment outcome, mutational analysis allows for optimised selection of subsequent line therapies.
|Title of host publication||Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia|
|Number of pages||29|
|Publication status||Published - 1 Jan 2015|
- BCR-ABL1 RT-qPCR
- BCR-ABL1 mutation analysis
- Molecular response
ASJC Scopus subject areas